Tejara Capital Ltd Buys New Stake in Heron Therapeutics, Inc. $HRTX
Tejara Capital Ltd has acquired a new stake in Heron Therapeutics, Inc. (NASDAQ:HRTX) during the second quarter, purchasing over 6.51 million shares valued at approximately $2.78 million, making it their 28th largest position. Other institutional investors also modified their holdings, with institutional ownership reaching 80.01%. Heron Therapeutics shares opened at $0.31, near a one-year low, after reporting a quarterly loss of $0.03 per share and revenue below analyst estimates, leading to a consensus "Hold" rating and an average price target of $2.00 from analysts.
H.C. Wainwright Maintains Heron Therapeutics(HRTX.US) With Hold Rating
H.C. Wainwright has reiterated its Hold rating for Heron Therapeutics (HRTX.US). The article does not provide further details on the reasons for this rating or any financial analysis.
Weekly Recap: Guidance withdrawn over CINVANTI patent and HRTX Q2 revenue $37.7M
Heron Therapeutics Inc (HRTX) has withdrawn its 2026 sales and Adjusted EBITDA guidance due to uncertainty surrounding the CINVANTI patent and an ongoing strategic review. The company reported Q2 revenue of $37.7M, including $11.1M from ZYNRELEF and $4.2M from APONVIE, with a cash balance of $42.7M. This decision follows their financial performance snapshot for Q2 2026.
HERON THERAPEUTICS INC : H.C. WAINWRIGHT CUTS TO NEUTRAL FROM BUY
H.C. Wainwright has downgraded Heron Therapeutics Inc. from a "Buy" rating to "Neutral." This change in analyst rating indicates a revised outlook on the company's stock performance. The article, sourced from Reuters, reports on this significant financial action.
H.C. Wainwright Downgrades Heron Therapeutics(HRTX.US) to Hold Rating
H.C. Wainwright has downgraded Heron Therapeutics (HRTX.US) from a Buy to a Hold rating. This change in rating reflects a revised outlook from the firm regarding the pharmaceutical company.
Heron Therapeutics Inc (HRTX) (Q2 2026) Earnings Call Highlights: Revenue Growth Amid Strategic ...
Heron Therapeutics reported Q2 2026 net revenue of $37.7 million, an increase from both the previous quarter and the prior year, driven by strong growth in ZYNRELEF and APONVIE sales, and improved Adjusted EBITDA. However, net revenue fell short of expectations due to slower growth in CINVANTI and ZYNRELEF, competitive pressures, and a negative court decision regarding CINVANTI patents, leading to the withdrawal of full-year guidance. The company amended its credit facility and is exploring strategic alternatives amidst market uncertainties.
Heron Therapeutics Q2 Earnings Call Highlights
Heron Therapeutics reported second-quarter net revenue of $37.7 million, exceeding prior-year figures but falling short of management expectations for key products. Sales of ZYNRELEF and APONVIE grew, while CINVANTI sales declined due to branded competition and increased generic risk following a Delaware court ruling. The company has appealed the decision, withdrawn its 2026 financial guidance, paused salesforce expansion, and is evaluating strategic alternatives while making debt payments under an amended credit facility.
Heron Therapeutics Q2 2026 Loss Widens 50.0% Beyond Estimates
Heron Therapeutics (NASDAQ: HRTX) reported a Q2 2026 diluted loss of $0.03 per share, exceeding analyst estimates by 50.0%, and revenue of $37.7 million, which fell 10.7% short of expectations. The company experienced a 1.6% stock drop as its largest segment, Oncology, saw a 15.9% year-over-year revenue decline, raising concerns despite a generally bullish analyst sentiment. Investors are advised to monitor the company's efforts to narrow losses and boost revenue growth.
Heron Therapeutics Withdraws 2026 Guidance as CINVANTI Patent Risk and Strategic Review Cloud Outlook
Heron Therapeutics has withdrawn its full-year 2026 financial guidance due to uncertainty surrounding potential generic competition for its key product, CINVANTI, following a recent court decision. The company's second-quarter revenue was below expectations, with strong growth in Acute Care revenue (ZYNRELEF and APONVIE) not fully offsetting declines in the Oncology segment (CINVANTI and SUSTOL). Heron is also evaluating strategic alternatives, which further contributes to the cloudy outlook for investors.
Heron Therapeutics earnings missed by $0.02, revenue fell short of estimates
Heron Therapeutics (NASDAQ: HRTX) reported a second-quarter EPS of $-0.030, missing analyst estimates by $0.02, and revenue of $37.67M, falling short of the consensus estimate of $42.13M. The company's stock has seen significant declines over the past 3 and 12 months. InvestingPro rates Heron Therapeutics' financial health as "fair performance."
Heron Therapeutics (HRTX) Reports Q2 Loss, Lags Revenue Estimates
Heron Therapeutics (HRTX) reported a Q2 loss of $0.03 per share, missing the Zacks Consensus Estimate of a $0.02 loss and representing an earnings surprise of -50.00%. The company also failed to meet revenue estimates, posting $37.67 million against an expectation of $42.39 million. HRTX shares have underperformed the S&P 500 significantly this year, losing about 62.3% compared to the index's 13.3% gain, and currently hold a Zacks Rank #3 (Hold).
Earnings call transcript: Heron Therapeutics misses Q2 2026 revenue forecast
Heron Therapeutics reported Q2 2026 revenue of $37.7 million, missing the forecast of $42.13 million, leading to an 18.74% drop in stock price. The company withdrew its full-year guidance due to uncertainty surrounding its CINVANTI franchise patent ruling, changes in spending, and a review of strategic alternatives. Despite the overall miss, products like APONVIE and ZYNRELEF showed significant year-over-year growth.
Heron Therapeutics: Q2 Earnings Snapshot
This article provides a Q2 earnings snapshot for Heron Therapeutics. No specific financial details or performance indicators are included in the provided content.
Heron Therapeutics reports Q2 2026 revenue $37.7M, withdraws 2026 guidance after patent ruling
Heron Therapeutics announced Q2 2026 net revenue of $37.7 million and a net loss of $5.5 million, ending the quarter with $42.7 million in cash. The company withdrew its full-year 2026 guidance following an unfavorable Delaware court decision impacting CINVANTI patents and is evaluating strategic alternatives. Despite growth in ZYNRELEF and APONVIE sales, overall Q2 results fell short of expectations, leading to a paused sales force expansion and amendments to its credit facility.
Heron Therapeutics Announces Second Quarter 2026 Financial Results
Heron Therapeutics announced its Q2 2026 financial results, with net revenue of $37.7 million, a 9% increase from Q1 2026. The company saw significant year-over-year growth in ZYNRELEF® (35%) and APONVIE® (74%) net revenue, but withdrew its full-year 2026 financial guidance due to uncertainty regarding CINVANTI® patents and a pause in sales force expansion. Heron Therapeutics is also exploring strategic alternatives to address its financial position.
Heron Therapeutics Q2 Revenue Rises To $37.7 Million
Heron Therapeutics reported a 1.3% year-over-year increase in Q2 2026 net revenue, reaching $37.7 million, with acute care and specific product revenues showing significant growth, although oncology revenue declined. The company posted a net loss of $5.5 million and withdrew its full-year 2026 guidance. Institutional investors showed mixed activity in HRTX stock during the quarter.
Heron Therapeutics: Q2 Earnings Snapshot
Heron Therapeutics Inc. (HRTX) reported a second-quarter loss of $5.5 million, translating to 3 cents per share. The pharmaceutical company, based in Cary, North Carolina, also announced revenues of $37.7 million for the period. This financial summary was generated using data from Zacks Investment Research.
Wall Street Zen Upgrades Heron Therapeutics (NASDAQ:HRTX) to Sell
Wall Street Zen has upgraded Heron Therapeutics (NASDAQ: HRTX) to a "sell" rating, contrasting with the broader analyst consensus of "hold." The biotechnology company recently missed quarterly earnings and revenue expectations, reporting a loss of $0.04 per share against a $0.03 consensus loss and $34.71 million in revenue against $36.72 million expected. Heron Therapeutics, which focuses on pain management and supportive care, has a current market capitalization of $92.9 million, with its shares trading near its 12-month low and below its 200-day moving average.
Heron Therapeutics Inc (HRTX) News, Articles, Events & Latest Updates
This article provides recent news and updates for Heron Therapeutics Inc (HRTX), including its Q2 2026 earnings report where it missed revenue estimates and its Q1 2026 report showing a loss and lagging revenue. The company's stock was also added to Zacks' "Strong Sell" list and saw its price target reduced by H.C. Wainwright.
Heron Therapeutics, Inc. (NASDAQ:HRTX) Receives Average Recommendation of "Hold" from Analysts
Heron Therapeutics (NASDAQ:HRTX) has received an average "Hold" recommendation from analysts, with a 12-month average price target of $2.50. The company recently reported a quarterly loss of $0.04 per share and revenue of $34.71 million, both below analyst expectations. Institutional investors and hedge funds own approximately 80.01% of the stock, with several major firms increasing their stakes.
Heron Therapeutics (NASDAQ:HRTX) Upgraded to Hold at Zacks Research
Zacks Research has upgraded Heron Therapeutics (NASDAQ:HRTX) from a "strong sell" to a "hold" rating, aligning with the broader analyst consensus. The biotechnology company, with a market capitalization of $96.8 million, recently missed its quarterly earnings and revenue estimates. Despite this, institutional investors hold a significant 80.01% of the stock.
Heron Therapeutics (HRTX) Projected to Post Quarterly Earnings on Monday
Heron Therapeutics (HRTX) is expected to report its Q2 2026 earnings before market open on Monday, August 10th, with analysts projecting a loss of $0.02 per share and revenue of $42.19 million. The company missed expectations in the previous quarter, reporting a $0.04-per-share loss against a $0.03 consensus and revenue of $34.71 million against an expected $36.72 million. HRTX shares recently traded near $0.51, and while the stock holds an average "Hold" rating and a $2.50 consensus price target, it has faced several recent downgrades.
Heron Therapeutics, Inc. Revenue Breakdown – NASDAQ:HRTX
Heron Therapeutics, Inc. (NASDAQ:HRTX) generated $154.90 million USD in revenue last year, primarily from its Therapeutic Innovations segment. This represents an increase from $144.28 million USD in the previous year. All reported revenue for the company originated from the United States.
Heron Therapeutics Inc (HRTX) Institutional Confidence
Heron Therapeutics Inc (HRTX) has an institutional shareholding score of 10.00, placing it first in the Biotechnology & Medical Research industry. The company's institutional shareholding proportion is 90.02%, showing a quarter-over-quarter increase of 5.58%. James Simons is the largest institutional shareholder, holding 0.91% of outstanding shares.
Heron Therapeutics Inc (HRTX) Financial Health: Profitability & Balance Sheet Analysis
Heron Therapeutics Inc (HRTX) currently holds a financial score of 7.51, ranking 112 out of 385 in the Biotechnology & Medical Research industry, indicating a weak financial status despite high operating efficiency. The company's latest quarterly revenue decreased by 10.78% year-over-year to $34.71 million, while its net profit saw a significant 407.82% year-over-year decline. Key financial metrics such as cash and cash equivalents, total assets, and free cash flow have not been disclosed by the company.
Heron Therapeutics Inc Revenue Breakdown – BX:AXD2
Heron Therapeutics Inc (BX:AXD2) generated 122.80 million CHF in revenue last year, primarily from its Therapeutic Innovations segment, which slightly decreased from 131.04 million CHF the previous year. The United States was the largest contributor to this revenue.
Heron Therapeutics Schedules Aug. 10 Webcast for Q2 Results
Heron Therapeutics (Nasdaq: HRTX) will report its second-quarter 2026 financial results on Monday, August 10, 2026, at 8:30 a.m. ET. The company will host a conference call and live webcast to discuss these results and recent business highlights. Investors can access the event via a registration-based dial-in or through the Investor Relations section of Heron's website, with an archived replay available for 60 days.
Heron Therapeutics Inc (HRTX) Cash Flow
This article provides a detailed cash flow statement for Heron Therapeutics Inc (HRTX), including quarterly and annual data for operating, investing, and financing activities. It also includes frequently asked questions explaining different types of cash flow and how to interpret them for HRTX. Investors can use this data to assess the company's financial health and stability.
Heron Therapeutics to Report Second Quarter 2026 Financial Results on Monday, August 10, 2026
Heron Therapeutics, Inc. announced it will host a conference call and live webcast on Monday, August 10, 2026, at 8:30 a.m. ET to report its second-quarter financial results and discuss recent business highlights. The commercial-stage biotechnology company focuses on developing and commercializing therapeutic innovations to improve patient care, particularly in acute care and oncology. An archive of the teleconference and webcast will be available on Heron's website for 60 days.
Heron Therapeutics Inc (AXD2) Q4 2022 Earnings Report - Results, Call & Slides
Heron Therapeutics Inc (AXD2) announced its Q4 2022 earnings, reporting an EPS of -€0.15 on revenue of €26.37M, beating analyst consensus for both metrics. The company's revenue grew 45.38% year-over-year. The next earnings date is estimated for August 11, 2026.
Heron Therapeutics Inc (AXD2) Q3 2025 Earnings Report - Results, Call & Slides
Heron Therapeutics Inc (AXD2) reported its Q3 2025 earnings, missing both EPS and revenue expectations. The company posted an actual EPS of -€0.09 against a consensus of -€0.01 and actual revenue of €33.56M, missing the expected €34.28M. The next earnings report is estimated for August 11, 2026.
Heron Therapeutics Inc (HRTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Heron Therapeutics Inc (HRTX), categorizing its income by business segments and geographic regions. The financial data, updated on April 6th, shows CINVANTI as the largest revenue contributor among its products, with all revenue originating from the United States.
HRTX|Heron Therapeutics Inc|Price:0.456|Chg%:-0.003
Heron Therapeutics Inc. (HRTX) is a commercial-stage biotechnology company trading at $0.456, experiencing a slight decline of 0.70%. The company is focused on improving patient lives through therapeutic innovations, particularly in acute care and oncology. Despite strong institutional ownership and high growth in revenue over the past three years, analysts predict a potential downward trend for the stock in the medium term, though two analysts currently rate it as "Buy" with a target price of $2.50.
Heron Therapeutics Inc (AXD2) Q4 2025 Earnings Report - Results, Call & Slides
Heron Therapeutics Inc (AXD2) reported its Q4 2025 earnings, meeting consensus EPS expectations of -€0.02, while beating revenue estimates with €35.65M against an expected €35.02M. The company experienced a slight year-over-year revenue decrease of -0.47%. The next earnings report is anticipated around August 11, 2026.
Heron Therapeutics Inc (AXD2) Q1 2024 Earnings Report - Results, Call & Slides
Heron Therapeutics Inc (AXD2) has released its Q1 2024 earnings report, surpassing analyst expectations for both EPS and revenue. The company reported an actual EPS of -€0.02, beating the consensus of -€0.07, and actual revenue of €30.37M, exceeding the expected €28.88M with a 17.07% year-over-year growth. The report includes details on the earnings call and slide deck for Q1 2024, and provides a schedule of upcoming earnings dates.
Heron Therapeutics Inc (HRTX) Q1 2024 Earnings Report - Results, Call & Slides
Heron Therapeutics (HRTX) reported strong Q1 2024 earnings, beating both EPS and revenue expectations. The company recorded an actual EPS of -$0.02 against a consensus of -$0.07, and revenue of $34.67 million, surpassing the expected $32.98 million. The report also highlights a significant year-over-year revenue growth of 17.07%.
Heron Therapeutics updates investors on business progress as development pipeline remains the key va
Heron Therapeutics is progressing its drug portfolio, focusing on operational execution and a long-term strategy for treatments in oncology support and pain management. The company's stock valuation is closely tied to its clinical development pipeline, regulatory milestones, and commercialization success. Investors are advised to consider the balance between near-term revenue and long-term prospects as the company navigates the biopharmaceutical industry's high R&D intensity and regulatory dependencies.
HRTX - Heron Therapeutics Inc Options
This page provides a detailed financial overview of Heron Therapeutics Inc. (HRTX), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators, insider and institutional ownership, and short interest data, alongside recent performance metrics over different timeframes.
Is Heron Therapeutics, Inc. (HRTX) Stock a Recovery Opportunity After Cinvanti Patent Court Ruling?
Heron Therapeutics (HRTX) faces a setback after a U.S. District Court ruled against it in Cinvanti patent litigation, leading H.C. Wainwright to lower its price target. The company plans to appeal the decision, asserting confidence in its legal arguments and intellectual property. Despite the ruling not impacting previous settlement agreements, the company is determined to defend its patents for its innovative therapies.
Heron Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard
Heron Therapeutics received a notice from Nasdaq on June 25, 2026, stating that its common shares failed to meet the minimum bid price requirement of $1.00 for 30 consecutive trading days. The company has 180 days, until December 22, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive days. Trading of HRTX shares continues on The Nasdaq Capital Market.
Heron Therapeutics (HRTX) Stock Sees Fair Value Cut After Cinvanti Patent Decision
Heron Therapeutics (HRTX) has seen its analyst fair value estimate cut from US$4.75 to US$3.00 per share following a Cinvanti patent decision that invalidated claims on two patents. This revision reflects legal risks, potential generic competition for Cinvanti (which accounts for 60% of sales), and changes to revenue growth, net profit margin, and discount rate assumptions. While H.C. Wainwright highlights appeal potential, Needham downgraded the stock to Hold due to the significant legal setback.
Heron Therapeutics Receives Nasdaq Minimum Bid Price Notification
Heron Therapeutics announced it received a notice from Nasdaq regarding its non-compliance with the minimum bid price requirement. The company has 180 calendar days, until December 23, 2024, to regain compliance, with a possible extension for another 180 days. Heron's common stock will continue to trade on the Nasdaq Global Select Market under the symbol "HRTX" during this period, and the notice does not immediately impact its listing.
Heron Therapeutics Receives Nasdaq Minimum Bid Price Notification
Heron Therapeutics received a notification from Nasdaq regarding its minimum bid price requirement. The article, published by MT Newswires, provides this brief update. Access to the full article is reserved for members.
Heron Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Forbes William P
This article provides a statement of changes in beneficial ownership of securities for Officer Forbes William P at Heron Therapeutics. The document details the modifications in his holdings.
Heron Therapeutics Inc Actuals & Estimates (NASDAQ:HRTX)
This article provides an overview of Heron Therapeutics, Inc. (NASDAQ: HRTX) stock, including its current price, market capitalization, historical performance, and analyst forecasts. It also details the company's financial actuals and estimates for earnings and revenue, noting past surprises and future expectations, but states the company does not pay dividends.
Heron Therapeutics Inc Actuals & Estimates (BX:AXD2)
This article provides an overview of Heron Therapeutics Inc. (BX:AXD2) stock, including its current price, market capitalization, analyst forecasts, and historical highs and lows. It also details the company's recent financial performance, such as earnings per share and revenue, and upcoming earnings report dates.
Enterprise value to revenue forward of Heron Therapeutics, Inc. – NASDAQ:HRTX
This article provides financial data specifically regarding the enterprise value to revenue forward metric for Heron Therapeutics, Inc. (NASDAQ: HRTX). It appears to be a stub or an entry on a financial data platform from TradingView, indicating that the value for this specific period is available upon navigation.
Nasdaq warns Heron Therapeutics (NASDAQ: HRTX) on sub-$1.00 bid price
Heron Therapeutics (NASDAQ: HRTX) has received a notice from Nasdaq regarding its failure to meet the minimum $1.00 bid price requirement, as its stock traded below this level for thirty consecutive days. The company has 180 calendar days, until December 22, 2026, to regain compliance by ensuring its closing bid price reaches at least $1.00 for a minimum of ten consecutive days. Failure to comply could lead to delisting, though the company may consider options like a reverse stock split and could be eligible for an additional compliance period.
Price to sales forward of Heron Therapeutics, Inc. – NASDAQ:HRTX
This article provides financial data, specifically the "Price to sales forward" for Heron Therapeutics, Inc. (NASDAQ: HRTX). It appears to be a financial snapshot from TradingView, offering a quick look at this metric, but without further details or analysis within the provided text.
Heron Therapeutics Stock - long-term strategy under pressure after reverse split and Nasdaq warning
Heron Therapeutics (HRTX) is facing a challenging long-term repositioning strategy after undergoing a 1-for-25 reverse stock split in 2024 to meet Nasdaq's minimum bid price requirements and receiving a Nasdaq listing deficiency notice. The company, focused on pain management and oncology supportive care, must balance advancing its product portfolio with controlling cash burn and securing funding. This situation is typical for smaller biotech companies that need to finance research, trials, and commercialization efforts with often limited revenue.
